project id: TCGA-TGCT; case submitter id: TCGA-2G-AAKD; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.82; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.35; rna integrity number: 7.2; age at index: 18; days to birth: -6814; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1979; age at diagnosis: 6814; ajcc clinical m: M1a; ajcc clinical n: N2; ajcc clinical stage: Stage III; ajcc clinical t: T2; ajcc pathologic m: M0; ajcc pathologic n: NX; ajcc pathologic stage: Stage III; ajcc pathologic t: T2; ajcc staging system edition: 4th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 6340.0; icd 10 code: C62.90; igcccg stage: Intermediate Prognosis; last known disease status: not reported; morphology: 9070/3; primary diagnosis: Embryonal carcinoma, NOS; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Testis, NOS; synchronous malignancy: No; tissue or organ of origin: Testis, NOS; tumor grade: Not Reported; year of diagnosis: 1997; alcohol history: Not Reported; is ffpe: false; weight: 30.0; composition: Not Reported; days to collection: 6032; days to sample procurement: 0; initial weight: 330.0; portion submitter id: TCGA-2G-AAKD-01A-31; percent lymphocyte infiltration: 40.0; percent monocyte infiltration: 20.0; percent necrosis: 10.0; percent neutrophil infiltration: 20.0; percent normal cells: 0.0; percent stromal cells: 30.0; percent tumor cells: 60.0; percent tumor nuclei: 60.0;